/ 2 items

#ZYME↓

Featured/ ZYME/ 11/17/2025 · 7:19 AM

Zymeworks & Jazz Pharmaceuticals Stocks Surge on Positive Cancer Trial Results

Zymeworks jumps 31% and Jazz Pharmaceuticals rises 26% after announcing successful Phase 3 trial results for Ziihera cancer treatment targeting stomach and esophageal cancers.

ZYME/ 10/24/2025 · 12:52 PM

H.C. Wainwright Rates Zymeworks a Buy on Promising ZW191 Cancer Drug Data

H.C. Wainwright sets $26 price target for Zymeworks after Phase 1 data shows ZW191 cancer drug outperforms FDA-approved competitor with 44% response rate.